Trials / Completed
CompletedNCT00761592
Comparison of Two Botulinum Type A Products in the Treatment of Blepharospasm
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 65 (actual)
- Sponsor
- Allergan · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This pilot study estimates the treatment effects of two different types of botulinum toxin type A in the treatment of Blepharospasm. Blepharospasm is characterised by excessive contraction of the muscles around the eye and can lead to repetitive blinking or sustained closure of the eyelids.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Botulinum Toxin Type A 900kDa | 6 to 16 injections, with maximum of 21, at a dose of ≥20U/eye (≥40U total dose) |
| BIOLOGICAL | Botulinum Toxin Type A 150kDa | 6 to 16 injections, with a maximum of 21, at a dose of ≥20U/eye (≥40U total dose) |
Timeline
- Start date
- 2006-07-01
- Primary completion
- 2008-01-01
- Completion
- 2008-01-01
- First posted
- 2008-09-29
- Last updated
- 2013-11-19
- Results posted
- 2009-07-09
Locations
3 sites across 1 country: Germany
Source: ClinicalTrials.gov record NCT00761592. Inclusion in this directory is not an endorsement.